Antibody Study for Gene Therapy in Muscle Diseases
Part of Genetic & congenital clinical trials.
This study measures your body's natural immune response to certain viruses used in experimental gene therapies for inherited muscle diseases. Results help doctors understand who might be a good candidate for these treatments in the future.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 6 and 59 years old
- You have been diagnosed with an inherited muscle or nerve disease
- You have not received any gene therapy or cell therapy treatments before
- You have signed an informed consent form agreeing to participate
- You have health insurance coverage
- For patients under 18, parents or guardians must agree you can participate
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a gene therapy for people with a specific mutation (S295L) in the SLC6A1 gene, which causes a neurodevelopmental disorder. The therapy aims to correct the genetic issue, and participants will be monitored closely for safety and effectiveness.
This trial tests a gene therapy that may help rebuild muscle and improve blood vessel growth in people ages 35 to 75. It's designed for those with stable health conditions and no history of cancer, heart disease, blood clots, or diabetes.
This trial tests a one-time gene therapy (SAR446268) for people with non-congenital myotonic dystrophy type 1. It aims to see if the treatment is safe and can improve muscle symptoms like stiffness and weakness.
This early-phase study tests a gene therapy meant to treat people who have IGHMBP2 gene changes. It aims to improve the way the nervous system works and to see if the treatment is safe, especially in young children.
This study tests a new gene therapy called BBM-D101 for boys with Duchenne muscular dystrophy. The goal is to see if it is safe and can help improve muscle function. It is for boys aged 4 to 8 who can still walk.
This trial tests whether giving a gene therapy before birth can help babies with GM1 gangliosidosis, a rare genetic disorder that damages the brain and body. It uses a harmless virus to deliver a working copy of the missing enzyme, aiming to slow or prevent disease progression.
Hear when a new Genetic Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.